Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Curved 150)
Navigation Links
Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Curved 150)
| Products | Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Curved 150) |
| Company | Medtronic Xomed, Inc. |
| Item | Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Curved 150) |
| Features | Curved 150. |
| Description | Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box. |
| Info | Medtronic Xomed, Inc. Customer Service: (800) 874-5797 Web site: http://www.xomed.com/ |
Related medicine products :
1. Wet-Field Hemostatic Eraser Bipolar Tip (18 gauge Straight w/45 bevel tip)
2. Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Straight, Long Shaft)
3. Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Curved 135)
4. Wet-Field Hemostatic Eraser Bipolar Tip
5. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
6. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Straight)
7. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 90)
8. Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 135)
9. Wet-Field Hemostatic Eraser Bipolar Tip (18 gauge Angled Shaft w/blunt tip)
10. Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Passive Aspirator)
11. Wet-Field Hemostatic Eraser Bipolar Tip (20 gauge Active Aspirator, Curved 150 with Reflux)
Breaking Medicine News(10 mins):Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3Health News:With Amino Acid Diet, Mice Improve After Brain Injury 2Health News:With Amino Acid Diet, Mice Improve After Brain Injury 3Health News:Lead Exposure May Affect Mental Health 2Health News:Are manometric findings different between the patients with erosive and nonerosive disease? 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 3Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 4
[0] The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance[0] With Amino Acid Diet, Mice Improve After Brain Injury[0] Lead Exposure May Affect Mental Health[0] Are manometric findings different between the patients with erosive and nonerosive disease?[0] Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy
Other Medicine News:Health News:Vivisimo Case Studies Detail Innovative Enterprise Search Applications by Medical Libraries, Women's Health Site 2Health News:Vivisimo Case Studies Detail Innovative Enterprise Search Applications by Medical Libraries, Women's Health Site 3Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 2Health News:Myostatin inhibitors may improve recovery of wartime limb injuries 3Health News:Leading Plastic Surgeons Reveal Revolution in Stem Cell Research Has its Roots in Beverly Hills Plastic Surgery 2Health News:Leading Plastic Surgeons Reveal Revolution in Stem Cell Research Has its Roots in Beverly Hills Plastic Surgery 3Health News:Free Teleseminar Explores Surrogacy Requirements, Rights, Rewards 2Health News:Health Partners Chooses Healthation's AboveHealth Provider Portal 2Health News:FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products 2Health News:FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products 3
Vivisimo Case Studies Detail Innovative Enterprise Search Applications by Medical Libraries, Women's Health SiteMyostatin inhibitors may improve recovery of wartime limb injuriesLeading Plastic Surgeons Reveal Revolution in Stem Cell Research Has its Roots in Beverly Hills Plastic SurgeryFree Teleseminar Explores Surrogacy Requirements, Rights, RewardsHealth Partners Chooses Healthation's AboveHealth Provider PortalFTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology 2Undocumented Hispanics Face Health Care Roadblocks in U S 60405 1Undocumented Hispanics Face Health Care Roadblocks in U S 60405 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 1Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 3BMP Sunstone Announces November Investor Conference Participation 14664 1BMP Sunstone Announces November Investor Conference Participation 14664 2
[0] Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia[0] Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture[0] Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |